XLO Xilio Therapeutics
- 0.917
- -0.133-12.64%
- 0.920
- +0.003+0.29%
Xilio Therapeutics News
Xilio Therapeutics | 10-Q: Quarterly report
Xilio Therapeutics | 8-K: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Xilio Therapeutics | EFFECT: Others
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Russo Rene
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Frankenfield Christopher James
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Brennan Kevin M.
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Luptakova Katarina
Xilio Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Xilio Therapeutics | ARS: Annual Report to Security Holders
Xilio Therapeutics | DEFA14A: Others
Xilio Therapeutics | DEF 14A: Definitive information statements
Xilio Therapeutics | 424B5: Prospectus
Xilio Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Gilead Sciences, Inc.(19.9%)
Xilio Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Rock Springs Capital Management LP(8.71%),Rock Springs Capital LLC(8.71%), etc.
Xilio Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner GILEAD SCIENCES, INC.
Xilio Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner GILEAD SCIENCES, INC.
Xilio Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Xilio Therapeutics | 10-K: Annual report
Xilio Therapeutics | 8-K: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
Xilio Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
